Garry E Menzel
Officer, Director at Tcr2 Therapeutics Inc. (TCRR)
Garry E Menzel has filed 31 insider reports with the SEC since January 2021, as director at Black Diamond Therapeutics, Inc. (BDTX), director at Stoke Therapeutics, Inc. (STOK) and director at Adaptimmune Therapeutics PLC (ADAP) and at 1 more company. Garry E Menzel made no open-market purchases or sales in the last 12 months. The latest filing, on June 29, 2026, reports grant or award at Black Diamond Therapeutics, Inc. (BDTX).
- Filings
- 31
- Companies
- 4
- Bought on market
- None
- Sold on market
- $145K
Companies where Garry E Menzel is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Director | $1.31 | Jun 29, 2026 | |||||
| Directorsince August 2020 | $26.81 | Jun 5, 2025 | |||||
| Directorsince June 2023 | 75,056 | $43.4K | Jul 1, 2024 | ||||
| Officer, Director | 0 | $102K | Jun 1, 2023 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Jun 26, 2026BDTXSEC Form 4 filed by Director Menzel Garry EForm 4Grant or award
- Jun 12, 2025BDTXSEC Form 4 filed by Director Menzel Garry EForm 4Grant or award
- Jun 3, 2025STOKSEC Form 4 filed by Director Menzel Garry EForm 4Grant or award
- Jul 1, 2024ADAPSEC Form 4 filed by Director Menzel Garry EForm 4Grant or award
- Jun 5, 2024STOKSEC Form 4 filed by Menzel Garry EForm 4Grant or award
- Jun 6, 2024BDTXSEC Form 4 filed by Menzel Garry EForm 4Grant or award
- Jul 10, 2023-$43.4KADAPSEC Form 4 filed by Menzel Garry EForm 4Open-market sale
- Jul 5, 2023ADAPSEC Form 4 filed by Menzel Garry EForm 4Grant or award
- Jul 3, 2023ADAPSEC Form 4 filed by Menzel Garry EForm 4Grant or award
- Jun 13, 2023STOKSEC Form 4 filed by Menzel Garry EForm 4Grant or award
- Jun 1, 2023ADAPSEC Form 4 filed by Menzel Garry EForm 4Grant or award
- Jun 1, 2023ADAPGarry E Menzel became an insiderForm 3New insider
- Jun 1, 2023TCRRSEC Form 4 filed by Menzel Garry EForm 4Sale back to the company
- May 16, 2023BDTXSEC Form 4 filed by Menzel Garry EForm 4Grant or award
- Dec 15, 2022TCRRSEC Form 4 filed by Menzel Garry EForm 4Grant or award
- Dec 13, 2022-$35KTCRRSEC Form 4: Menzel Garry E sold $35,034 worth of shares (31,938 units at $1.10) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 138,871 units to satisfy withholding obligationForm 4Open-market sale10b5-1 plan
- Dec 8, 2022-$23.4KTCRRSEC Form 4: Menzel Garry E sold $23,360 worth of shares (18,425 units at $1.27) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 170,809 units to cover withholding taxForm 4Open-market sale10b5-1 plan
- Dec 6, 2022-$31.8KTCRRSEC Form 4: Menzel Garry E sold $31,784 worth of shares (23,416 units at $1.36) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 189,234 units (withholding tax)Form 4Open-market sale10b5-1 plan
- Dec 2, 2022-$11.7KTCRRSEC Form 4: Menzel Garry E converted options into 221,058 shares and sold $11,687 worth of shares (8,408 units at $1.39) as part of a pre-agreed trading plan (tax liability)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Nov 17, 2022TCRRSEC Form 4 filed by Menzel Garry EForm 4Grant or awardSale back to the company
- Jul 5, 2022TCRRSEC Form 4: Menzel Garry E gifted 265,459 shares and received a gift of 265,459 sharesForm 4Gift
- Jun 10, 2022BDTXSEC Form 4 filed by Menzel Garry EForm 4Grant or award
- Jun 7, 2022STOKSEC Form 4 filed by Menzel Garry EForm 4Grant or award
- Feb 28, 2022TCRRSEC Form 4: Menzel Garry E was granted 1,425 shares, increasing direct ownership by 0.79% to 180,932 unitsForm 4Grant or award
- Dec 10, 2021TCRRSEC Form 4: Menzel Garry E exercised 175,000 shares at a strike of $0.74 and was granted 422 shares, increasing direct ownership by 4,294% to 179,507 unitsForm 4Grant or awardExercise or conversion of a derivative
- Jun 8, 2021STOKSEC Form 4 filed by Menzel Garry EForm 4Grant or award
- Jun 18, 2021BDTXSEC Form 4 filed by Menzel Garry EForm 4Grant or award
- Apr 20, 2021BDTXSEC Form 4 filed by Menzel Garry EForm 4Grant or award
- Feb 28, 2021TCRRSEC Form 4: E Garry Menzel was granted 1,818 units of Common Stock, increasing direct ownership by 80% to 4,085 unitsForm 4Grant or award
- Aug 13, 2020STOKSEC Form 4 filed by E Garry MenzelForm 4Grant or award
- Aug 13, 2020STOKSEC Form 3: E Garry Menzel claimed no ownership of No securities beneficially heldForm 3New insider
Also sits on boards with
Officers and directors who share two or more companies with Garry E Menzel.
- Ali Behbahani2 shared: BDTX, ADAP
- Thomas Leggett2 shared: STOK, BDTX
- Priti Hegde2 shared: ADAP, TCRR
- Andrew R Allen2 shared: ADAP, TCRR
Compare Garry E Menzel with
- Garry E Menzel vs Ali Behbahani2 shared
- Garry E Menzel vs Thomas Leggett2 shared
- Garry E Menzel vs Priti Hegde2 shared
- Garry E Menzel vs Andrew R Allen2 shared
- Garry E Menzel vs Barry Ticho1 shared
- Garry E Menzel vs Jonathan Allan1 shared
Other insiders at the same companies
- Barry TichoSTOK
- Jonathan AllanSTOK
- Alexander CumboSTOK
- Prakash RamanBDTX
- Kaye Edward M. MDSTOK
- Seth Loring HarrisonSTOK
- Thomas McCauleySTOK
- Samarth KulkarniBDTX
- Kapil DhingraBDTX
- Shannon CampbellBDTX
- Arthur TzianabosSTOK
- Julie SmithSTOK
- Arthur A LevinSTOK
- Adrian R. KrainerSTOK
- Jennifer BursteinSTOK
Questions about Garry E Menzel
- What is Garry E Menzel's role at Tcr2 Therapeutics Inc.?
- Garry E Menzel reports to the SEC as officer and director at Tcr2 Therapeutics Inc. (TCRR), according to the latest filing on June 1, 2023. Garry E Menzel has also filed as director at Black Diamond Therapeutics, Inc. (BDTX), director at Stoke Therapeutics, Inc. (STOK) and director at Adaptimmune Therapeutics PLC (ADAP).
- How many shares does Garry E Menzel own?
- After the latest filing that states it, Garry E Menzel directly owned 75,056 shares of Adaptimmune Therapeutics PLC (ADAP). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Garry E Menzel bought or sold stock recently?
- The most recent open-market sale was on July 10, 2023: sold 47,702 shares of Adaptimmune Therapeutics PLC (ADAP) for $43.4K at an average of $0.91.
- How do I get alerts when Garry E Menzel files?
- Follow Garry E Menzel on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Garry E Menzel (SEC CIK 0001556064). Totals count each trade once, skipping amendments whose original is on file, from Jan 27, 2021 on. View on SEC EDGAR · Get this as JSON